osteosarcomaとは 意味・読み方・使い方

It is predicted that the effectiveness of the chemotherapy of the osteosarcoma by an anticancer agent is low when the expression level of peroxiredoxin 2 (PRDX2) is measured, and the expression level of the peroxiredoxin 2 is increased.例文帳に追加

ペロキシレドキシン２（ＰＲＤＸ２）の発現量を測定し、前記ペロキシレドキシン２の発現量が上昇している場合、骨肉腫に対する抗癌剤の化学療法奏効性が低いと予測することを特徴とする。 - 特許庁

The invention relates to the RNAi sequences useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma, and Alzheimer's disease.例文帳に追加

前立腺癌、骨肉腫などの肉腫、腎細胞癌、乳癌、膀胱癌、肺癌、結腸癌、卵巣癌、未分化大細胞リンパ腫及びメラノーマを含む様々な種類の癌の治療、及びアルツハイマー病の治療における治療薬として有用であるＲＮＡｉ配列。 - 特許庁

The RNAi sequences are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, undifferentiated large cell lymphoma and melanoma, and Alzheimer's disease.例文帳に追加

前立腺癌、骨肉腫などの肉腫、腎細胞癌、乳癌、膀胱癌、肺癌、結腸癌、卵巣癌、未分化大細胞リンパ腫及びメラノーマを含む様々な種類の癌の治療、及びアルツハイマー病の治療における治療薬として有用であるＲＮＡｉ配列。 - 特許庁

There is provided the treating agent for the tumor, especially the breast cancer, osteosarcoma or prostatic cancer, composed of a nucleotide sequence having ≥70% identity with a nucleotide sequence represented by sequence identification number 2 which is a complementary chain sequence of miR-625*, and containing a nucleic acid having an activity in inhibiting functions of the miR-625* or a vector allowing expression thereof.例文帳に追加

miR-625*の相補鎖配列である配列番号２で表されるヌクレオチド配列と70%以上の同一性を有するヌクレオチド配列からなり、且つmiR-625*の機能を阻害する活性を有する核酸またはそれを発現し得るベクターを含む、腫瘍、特に乳がん、骨肉腫または前立腺がんの治療剤。 - 特許庁

To provide an osteoplasty accelerator useful for prevention and therapy of bone disease, fracture of the bone, refracture, osteoporosis, osteomalacia, Paget disease, bone tissue restoring after myeloma, osteosarcoma, bone tissue restoring after extirpating metastatic lesion such as carcinoma mammae, pulmonary cancer and restoring of periodontal tissue in periodontosis.例文帳に追加

骨疾患、例えば骨折、再骨折、骨粗鬆症、骨軟化症、Ｐａｇｅｔ病などの予防および治療、さらに骨髄腫、骨肉腫などの外科手術後の骨組織修復、および乳癌、肺癌などの骨転移巣の摘出後の骨組織修復、および歯周疾患などにおける歯周組織の再生に有用な骨形成促進剤を提供する。 - 特許庁

To provide usage of RNAi sequences as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, undifferentiated large cell lymphoma and melanoma, and Alzheimer's disease, and a method for treating these diseases by administration of RNA molecules having RNAi activity to those individual including human individual in need of these treatment.例文帳に追加

本発明は、前立腺癌、骨肉腫などの肉腫、腎細胞癌、乳癌、膀胱癌、肺癌、結腸癌、卵巣癌、未分化大細胞リンパ腫及びメラノーマを含む様々な種類の癌の治療及びアルツハイマー病の治療におけるＲＮＡｉ配列の使用、並びにＲＮＡｉ活性を有するＲＮＡ分子を、これらの治療を必要とするヒト個体を含む個体に投与することによる、これらの病気を治療する方法を提供する。 - 特許庁

To provide a method for using RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma, and Alzheimer's disease, and to provide a method for treating individual, including human individual in need of such treatment by administering an RNA molecule having RNAi activity.例文帳に追加

本発明は前立腺癌、骨肉腫などの肉腫、腎細胞癌、乳癌、膀胱癌、肺癌、結腸癌、卵巣癌、未分化大細胞リンパ腫及びメラノーマを含む様々な種類の癌の治療及びアルツハイマー病の治療におけるこれらのＲＮＡｉ配列の使用、並びにＲＮＡｉ活性を有するＲＮＡ分子を、これらの治療を必要とするヒト個体を含む個体に投与することによる、これらの病気を治療する方法を提供する。 - 特許庁

The nonpeptidic NK1 receptor antagonist and substance P are used as pharmaceutical compounds inducing apoptosis of mammal tumor cells, and use of the substance P antagonist concretely nonpeptidic NK1 receptor antagonist, in human cancer therapy, for instance therapy of infiltrative melanoma, neuroblastoma, neuroglioma, Hodgkin lymphoma, acute lymphoblastic leukemia, astroglioma, rhabdomyosarcoma, human mammary cancer, Burkitt lymphoma, lung cancer, Edwing lymphoma and human osteosarcoma, is provided.例文帳に追加

哺乳動物の腫瘍細胞のアポトーシスを誘発する医薬化合物として、非ペプチド性ＮＫ１受容体拮抗物質及びサブスタンスＰを使用し、ヒトの癌治療、例えば浸潤性悪性黒色腫、神経芽細胞腫、神経膠腫、ホジキン(Hodgkin)リンパ腫、急性リンパ芽球性白血病、星細胞腫、横紋筋肉腫、ヒト乳癌、バーキット(Burkitt)リンパ腫、肺癌、エドウィング(Edwing)肉腫、ヒト骨肉腫の治療におけるサブスタンスＰ拮抗物質、具体的には非ペプチド性ＮＫ１受容体拮抗物質の使用。 - 特許庁